| Name | Title | Contact Details |
|---|
We combine the personal care found in private dermatology practices with the benefits of a network of physicians working together.
Orca Bio is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely replace patients` diseased blood and immune system with a healthy one.
At Precision for Medicine, we help our pharmaceutical and life sciences clients innovate, develop, and commercialize next generation medical products. Backed by a diverse team of experts across the spectrum of the healthcare marketplace, we provide a comprehensive and integrated set of services that help accelerate research, enable market adoption, enhance patient outcomes, and realize the full commercial potential of new therapies and products.
Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.
Since its establishment in 2004, Ray has been leading the global market in digital dentistry by proposing a new standard for dental imaging solutions through state-of-the-art technology.